Skip to main content

Table 2 Neutralization titer against HIV-1 clinical isolates in BALB/c mice

From: Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine

Vaccine groups

Neutralization titer against HIV-1 isolates

 

XJDC6371

XJDC6431

XJDC0793

CBJB105

CBJB248

020101300

SV145

< 6

< 6

< 6

< 6

< 6

> 12

SV145-10M

> 12

> 24

> 24

> 24

> 24

> 12

SV145M1&2

< 6

> 24

> 24

> 24

> 24

> 24

SV145M1

< 6

> 24

> 24

> 24

> 24

> 24

SV145M2

< 6

> 12

> 12

> 12

> 12

> 12

SV145M3

< 6

< 6

< 6

< 6

> 12

> 12

SV145M4

< 6

< 6

< 6

< 6

> 12

> 12

SV145M5

< 6

< 6

< 6

< 6

< 6

< 6

  1. The neutralization was conducted by using a panel of clinical isolates in PBMCs with 50% inhibitory dose. Gp145-10 M, gp145M1&2, gp145M1 and 145M2 groups could neutralize HIV-1 isolates at the highest titer of 1:24, other than XJDC6371. The single N-glycosylation site deletion in the V1 loop designated as gp145M2 could induce broader neutralizing antibodies against five clinical isolates at a titer of 1:12.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us